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Summary  
Scope: The aim of this study was to identify if specific regions of the human genome 
were sensitive to folate status by displaying changes in their DNA methylation 
patterns in response to continued folic acid supplementation during pregnancy.  
Methods and results: Samples (n = 119) from a previous randomized controlled trial 
in pregnancy were used to compare the DNA methylation profiles of the same woman 
pre- versus post- folic acid intervention.  Candidate genes were identified from the 
literature and a pilot genome wide screen of 6 women (3 from each of the folic acid 
and placebo arms of the trial).  We did not observe consistent DNA methylation 
changes in response to folic acid intervention at any of our candidate genes (RASA4, 
DHFR, DHFR2, RASSF1A, EIF2C3, ATPF1).  We did identify a 40% decrease in 
DNA methylation at the RASA4 promoter correlating with a 3.5 fold increase in its 
mRNA abundance in an in vitro cell culture model.  
Conclusion: Continued folic acid intervention over a 22-week period did not appear 
to significantly influence the DNA methylation status of six candidate genes in blood 
samples of women compared to placebo. However, DNA methylation may play a role 
in the gene expression control of the RASA4 gene.  
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1 Introduction 
DNA methylation is a mechanism used by cells in combination with histone and 
chromatin modifications to control gene expression. Its role in the control of gene 
expression is best characterised in relation to cellular differentiation and in the mono-
allelic expression of specific parent-of-origin genes that are referred to as imprinted 
regions of the genome (Klose and Bird, 2006).  The process of DNA methylation is 
the addition of a methyl group to cytosine residues usually in the context of a CpG.  
However, it is now known that methylation can occur outside the CpG context, to 
other DNA bases and extends beyond just a simple methyl group (Lister et al., 2009, 
Wu et al., 2016, Dominissini et al., 2016).  Research over the last decade has revealed 
that the DNA methylation signatures across the genome, often referred to as the 
Methylome, have different associations with gene expression control depending on 
where in the gene they occur i.e., in the promoter region or in the body of the gene 
(Ball et al., 2009), and they also appear to be context specific.  Despite the 
complexity, it is accepted that changes to gene-specific DNA methylation patterns can 
potentially have an impact on the expression level of a particular gene and therefore, 
can influence cellular phenotypes.  The possibility that environmental influences such 
as diet and lifestyle can have an influence on DNA methylation patterns has 
influenced a plethora of research in this area. Furthermore, these changes can have 
consequences not only for individual cell lineages, but can manifest across 
generations.   
There is convincing epidemiological data to support the 'fetal origin of adult 
disease' hypothesis i.e., the concept that the in utero environment can impact not only 
the developing embryo but also the subsequent offspring across a number of 
generations (Barker, 1990). Deciphering the molecular mechanism that mediates this 
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phenomenon is challenging, but the modifications to DNA methylation patterns has 
been an attractive model. Amongst the environmental influences that have been 
proposed to have an impact on DNA methylation, an individual’s folate status has 
received particular attention (Friso et al., 2017). Folate is metabolised through the 
One Carbon metabolism (OCM) pathway.  This pathway supplies the 1C units (one-
carbon) required for nucleotide synthesis, methylation reactions, cysteine through 
trans-sulphuration of homocysteine and it is a contributor to NADPH production 
(Bailey et al., 2015, Fan et al., 2014).  As folate supplies the methyl groups for 
methylation reactions it has been proposed as one of the nutrients that could have a 
direct effect on the DNA methylation levels of an individual and/or their offspring.  
Genomic regions that are potentially sensitive to folate status are referred to here as 
Folate Sensitive-Differentially Methylated Regions (FS-DMR).  In support of this 
hypothesis, a number of animal models have demonstrated that maternal diet can have 
trans-generational effects on the methylation patterns of the subsequent offspring 
(Parle-McDermott and Ozaki, 2011, Holland et al., 2016, Barua et al., 2016). 
Providing equivalent evidence from human studies has proven to be considerably 
more challenging.  It is clear that the DNA methylation patterns of individuals do 
change as they age (Jones et al., 2015) but evidence supporting folate status having a 
direct impact on human DNA methylation patterns is limited. Many studies have used 
HPLC, labelling methods (Parle-McDermott A and Ozaki M, 2011, Friso et al., 2002, 
Jacob et al., 1998, Rampersaud et al., 2000) or LINE-1 methylation as a proxy for 
global methylation (Badiga et al., 2016), performed gene-specific analyses using 
known imprinted genes (Steegers-Theunissen et al., 2009, McCullough et al., 2016, 
Pauwels et al., 2017) or have applied Illumina Beadchip arrays (Fryer et al., 2011, 
Joubert et al., 2016). A study by Amarasekera et al. (2014) did identify the region 
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upstream of ZFP57 as a hypomethylated FS-DMR in immune cells isolated from cord 
blood.  Zhong et al. (2017) showed in a study of ten individuals that B-vitamins could 
attenuate fine-particle induced DNA methylation changes in CD4+ helper cells. 
Joubert et al. (2016) identified a number of FS-DMR using Illumina Beadchip arrays 
in the cord blood of a large newborn cohort (n = 1,988) with known maternal folate 
levels.  Verification of reported FS-DMR to date, remain to be confirmed in other 
cohorts and with alternative technical methods. None of these studies so far have 
utilised samples from a folic acid intervention study to identify FS-DMR.  
We report here the use of a folic acid intervention trial to assess candidate FS-
DMRs identified from a pilot genome-wide screen and the literature.  
 
2 Materials and methods 
2.1 Participants 
The genomic DNA used in this investigation was extracted using available blood 
samples from the Folic Acid Supplementation in the Second and Third Trimesters 
(FASSTT) randomized controlled trial in pregnancy, as previously published, with 
appropriate informed consent and ethical approval to cover the current analysis 
(McNulty et al., 2013, Pentieva et al., 2016). The FASSTT trial was conducted in 
2006-7 and involved healthy women with uncomplicated pregnancy who were 
recruited at week 14 of gestation.  All women in the trial had taken folic acid (FA) 
supplements at a dose of 400 g/d during the first trimester of pregnancy. Exclusion 
criteria included having taken a dose of FA higher than 400 g/d, were taking 
medication that is known to interfere with folate metabolism (including aspirin, anti-
acids, aminopterin, pyrimethamine, phenytoin, methotrexate, sulfasalazine, 
phenobarbital or primidone), had undergone in vitro fertilization or had previously 
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had a pregnancy affected by a neural tube defect. Women were randomly allocated to 
continue to receive a FA supplement of 400 g/d for the remainder of their pregnancy 
(n = 59) or placebo (n = 60). A non-fasting blood sample was taken at the beginning 
of the trial i.e., at gestation week 14 (pre-intervention) and at week 36 (post-
intervention) (n = 119).  Plasma homocysteine, serum folate, and red-cell folate 
(RCF) level measurements were previously determined (McNulty et al., 2013) and 
available for this study.  
 
2.2 Genomic DNA Isolation from Buffy Coat 
Genomic DNA was isolated from frozen buffy coat samples as follows. Samples were 
thawed quickly in a 37°C water bath. A 20 μL volume of proteinase K was added to 
each sample in order to homogenize the blood clots found in the samples before DNA 
extraction. DNA was extracted using the Qiagen® FlexiGene DNA Kit as 
recommended by the manufacturer.  DNA concentration was determined using a 
Nanodrop 1000 Spectrophotometer instrument.  All samples were within an A260/280nm 
ratio of 1.8-2.1. Integrity of the genomic DNA was also assessed by electrophoresis 
on a 1% agarose gel.   Extracted DNA samples were stored at -20°C. 
 
2.3 Pilot Genome-wide DNA methylation analysis  
2.3.1 Selection of samples 
Our approach to identify potential novel Folate Sensitive-Differentially Methylated 
Regions (FS-DMR) was to compare DNA samples from the same individual pre- and 
post- intervention.   From the entire FASSTT cohort, 12 samples were selected from 6 
women, all of which displayed low baseline levels of RCF and serum folate prior to 
intervention to maximize the potential to identify FS-DMR (Table 1). Of these, 6 
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samples were from 3 women in the continuation of FA supplementation arm of the 
trial who had the greatest response in terms of their RCF and serum folate levels post-
intervention compared to baseline.  The remaining 6 samples were from 3 women in 
the placebo arm of the trial that had a decline in serum folate compared to baseline 
that was typical of all pregnant women in the placebo group.  
 
2.3.2 Methylated DNA Immunoprecipitation 
Immunoprecipitation of methylated DNA (MeDIP) and enrichment verification by 
qPCR is described in the Supplementary Information.  
 
2.3.3 Microarray analysis 
The MeDIP and Input DNA (sample without antibody) samples were processed by 
the Roche NimbleGen DNA Methylation Service as follows: MeDIP samples were 
labelled using Cy5 random nanomers, while Input DNA was labelled with Cy3 
nanomers. Input and MeDIP fractions for each sample were mixed and hybridised to 
the array using a Precision Mixer Alignment Tool (PMAT). Each PMAT was washed 
and incubated at 42°C in a Roche Hybridisation system for 16 hours. All 12 samples 
were loaded into a NimbleGen MS 200 Microarray Scanner in a one Slide Magazine. 
Image files were extracted and processed using DEVA software. Data was returned in 
the form of pair files, processed peak files, Signal Map GFF files, and promoter 
reports.  
 
2.3.4 MeDIP microarray data analysis 
A number of technical and consistency filters were applied sequentially to select 
candidate FS-DMR from the pilot genome wide screen (Supplementary Information 
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Figure 1).  MeDIP microarray data was received in several raw and processed file 
formats, including Microsoft Excel files containing annotated information for each 
“peak” i.e., groups of probes across a genomic region that showed a four-fold change 
in DNA methylation enrichment compared to Input. Each peak consisted of a number 
of probes (4 or higher) that spanned a given genomic region.  Each probe was 100 bp 
in length.  The cut-off enrichment peak score was set at 2.0 i.e., a DNA region scoring 
below this was deemed unmethylated. The criteria used for the identification of 
putative FS-DMR, was to compare the peak scores of the pre- versus post- 
intervention sample in each individual and those sites that showed a consistent DNA 
methylation change in all three individuals in the continued FA intervention arm but 
not in the placebo arm of the trial would be deemed a candidate FS-DMR for 
verification in all samples in the FASSTT trial. Identification of putative FS-DMR 
from analysis of the peak fold changes would then prompt a more in-depth analysis of 
the raw data.  A number of macros were written using Visual Basic 6.0 to aid with 
these comparisons. 
A list of peak regions were identified that showed a consistent DNA 
methylation change based on peak score comparisons pre- and post-intervention in the 
folic acid intervention samples but not in placebo. A fold change was generated by 
dividing the peak score of the post-intervention sample with the peak score of the pre-
intervention sample from the same individual.   The cut-off was ≥ 1.2 fold change in 
all three samples in the intervention group and ≤ 1.0 for the same probe in all three 
samples in the placebo. Apart from fold differences in peak regions, an On/Off and 
Off/On lists were also generated by identifying peak regions that did or did not appear 
in the pre-intervention versus post-intervention sample following MeDIP respectively. 
Candidate FS-DMR identified from these analyses then underwent a more in-depth 
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analysis of the probe distribution within each peak to assess whether the DNA 
methylation changes detected arose from the same or different probes in that peak 
region as the DEVA software gives the same gene name to groups of probes 
representing different CpG sites.  Candidates only remained if the same CpG sites 
were differentially methylated across samples.  This final analysis was carried out 
using the raw data on the peak-probe relationships contained in the Signal Map GFF 
files.  A False Discovery Rate was not applied as we did not expect a large number of 
false positives following statistical and technical filtering.   
 
2.4 RASA4 gene expression and DNA methylation analysis in a cell 
culture model 
2.4.1 De-methylation cell culture conditions 
Preliminary experiments were performed in HEK 293 (Human Embryonic Kidney) 
cells to assess the cytotoxicity of 5-azacytidine at different concentrations over a 7-
day time period and to ensure that the cells remained in log phase throughout the 
experiment. A 5M concentration of 5-azacytidine was determined to be the optimal 
concentration as assessed by a crystal violet assay (data not shown). HEK 293 cells 
were cultured in T75 flasks in Dulbecco’s Modified Eagle Medium (DMEM, Gibco) 
supplemented with 10% (v/v) foetal bovine serum, 1% (v/v) L-glutamine (Sigma-
Aldrich) and 1% (v/v) sodium pyruvate (Sigma-Aldrich) and allowed to attach prior 
to exposure to 5-azacytidine.  Cells were exposed to 5 M 5-azacytidine or acetic acid 
alone over a 7-day period with daily media changes due to the short half-life of the 
drug (Komashko and Farnham, 2010). Nucleic acid extractions were performed on 
day 7. The experiment was performed on two separate occasions.   
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2.4.2 RASA4 gene expression analysis by RT-qPCR 
Gene expression was assessed using Reverse Transcription-quantitative PCR (RT-
qPCR).  RNA was extracted from 5-azacytidine treated HEK 293 cells using Bioline’s 
Isolate II RNA mini kit. Integrity of the RNA was verified by electrophoresis on a 1% 
agarose gel and stained with ethidium bromide. The RNA was treated with DNase I 
(Sigma-Aldrich) prior to conversion to cDNA using a Bioline Superscript kit 
according to the manufacturer's instructions.  DNase-treated RNA (1µg) was 
transferred to a tube containing a mix of 2µl random hexamers (50ng/µl) and 4µl 
oligo-DT (270ng/µl). After incubation for 70°C for 5 minutes, samples were cooled 
on ice and added to a reaction containing 4µl Reaction Buffer (5x), 1µl RiboSafe 
RNase inhibitor (40u/µl) 1µl Bioline Bioscript reverse transcriptase enzyme 
(200u/µl), 1µl dNTPs (10mM), and 1.5µl nuclease-free water. Samples were 
incubated under the following programme: 10 minutes, 25°C; 60 minutes, 42 °C; and 
15 minutes, 70°C.  
An intron spanning RT-qPCR assay was used to verify the elimination of any 
potentially contaminating genomic DNA. All RT-qPCR reactions were carried out on 
the Roche 480 Lightcycler machine with assays designed by the Universal 
ProbeLibrary Design Centre. Each reaction contained a 1/10 dilution of the supplied 
and recommended probe, 2x Probe Master, 2.5mM MgCl2, and 1μl cDNA. 
 
2.4.3 RASA4 DNA methylation analysis  
DNA was extracted from HEK 293 cells using the Qiagen® FlexiGene DNA Kit as 
recommended by the manufacturer. DNA was RNase-treated with 25 μg 
Ribonuclease (Sigma-Aldrich) for 30 minutes at 37°C and was then ethanol 
precipitated with 0.3 M sodium acetate and 2 volumes of isopropanol. DNA was 
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quantified and checked for quality as described above and subsequently prepared for 
site-specific DNA methylation analysis as described below.  
 DNA for SMART-MSP underwent sodium bisulfite treatment using the 
Qiagen® Epitect kit according to the manufacturer’s instructions except that 1 g of 
DNA was used and the final elution was in a 100 l volume of molecular biology 
grade water. 
 
2.5 DNA methylation analysis of candidate FS-DMR 
Candidate FS-DMR were identified from the pilot genome-wide DNA methylation 
analysis (Section 2.3), were selected from the literature (Fryer et al., 2011; Parle-
McDermott et al., 2011; Vineis et al., 2011) and from the OCM pathway. Candidates 
were selected following a literature survey (Parle-McDermott et al., 2011) to identify 
those gene-specific sites that had previously shown a DNA methylation change that 
was potentially driven by changes in folate status. These included RASSF1A (Ras 
associated domain family member 1 alpha), EIF2C3 (Eukaryotic translation initiation 
factor 2C, 3) and ATPF1 (ATPase synthase H+ transporting, mitochondrial Fo 
complex, subunit B1).  Two enzymes from OCM were also included; DHFR 
(Dihydrofolate reductase) and DHFR2 (formerly known as DHFRL1: Dihydrofolate 
folate reductase like-1).  The DNA methylation status of candidate FS-DMR were 
assessed in the FASSTT cohort using either Sensitive Melting Analysis after Real 
Time-Methylation Specific PCR (SMART-MSP) analysis or Methylation Sensitive-
High Resolution Melting (MS-HRM) analysis on the Roche Lightcycler® 480 
instrument.   
 
2.5.1 SMART-MSP 
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SMART-MSP assays were designed and performed according to Kristensen et al 
(2008). The target region primer sequences and optimized annealing temperatures 
were as follows: RASA4 Forward 5’-CGTGGAGGGGAAGAACCT-3’, Reverse 5′-
TCCACCTTCACGATGCAGTA-3′, Tm 56°C; DHFR Forward 5′-
GAGGGTTTTCGTTTTCGTTCG-3′, Reverse 5′-
CAAATAAACCCTAACGCTACAACG-3′, Tm 54°C; DHFR2 Forward 5′-
GGGTTAGGGTTAAAGCGATTTTCGT-3′, Reverse 5′-
AAACAAAAACCGCACAAACGCG-3′, Tm 58°C.  Each assay was designed to 
only amplify methylated DNA following bisulfite treatment. The COL2A1 primer 
sequences were as previously described (Kristensen et al., 2008) and are designed to 
assess the amount of amplifiable bisulfite converted DNA in the sample regardless of 
its methylation status (Tm 63°C).  The amplification and melting conditions were 
optimized using 100% and 0% DNA methylation standards (Qiagen®). Genomic 
DNA was bisulfite treated using the Qiagen Epitect Fast Bisulfite conversion kit.  A 
2.5 μL volume (25 ng) of bisulfite treated DNA (theoretical amount) was used per 
reaction, giving a final volume of 10 μL. A positive 100 % methylated control and 
negative template control using 2.5 μL H2O instead of DNA was also included. All 
samples were carried out in duplicate. Template DNA was initially denatured at 95°C 
for 10 min, followed by 45 amplification cycles, followed by high-resolution melting 
analysis on the Lightcycler® 480. Each cycle consisted of template denaturation 
(95°C for 10 s), primer annealing (Tm for 15 s) and extension (72°C for 15 s). This 
was followed by high-resolution melting analysis. High-resolution melting settings 
consisted of 95°C for 1 min, 40°C for 1 min, 70°C for 5 s and continuous acquisition 
to 95°C (ramp rate 0.02 °C/s), followed by cooling at 40°C for 10 s. Crossing point 
(Cp) values and melting temperature for the DNA samples were assigned 
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automatically by the Lightcycler ® 480 Software. Cp values were averaged and 
methylation values were quantified using the 2(-ΔΔCp) quantification approach 
(Kristensen et al., 2008).  
 
2.5.2 MS-HRM 
Genomic DNA used for MS-HRM assays was bisulfite treated using Imprint® DNA 
Modification Kit (Sigma-Aldrich) according to the manufacturers’ instructions. A 1 
μL volume of bisulfite treated DNA (500 ng concentration) was used per reaction, 
giving a final volume of 10 μL. A negative-template control using 1 μL H2O instead 
of DNA was also included. Template DNA was initially denatured at 95°C for 10 
min, followed by 45 amplification cycles, followed by high-resolution melting 
analysis on the Lightcycler® 480. Each cycle consisted of template denaturation 
(95°C for 10 s), primer annealing (Tm for 15 s) and extension (72°C for 15 s). This 
was followed by high-resolution melting analysis. High-resolution melting settings 
consisted of 95°C for 1 min, 40°C for 1 min, 70°C for 5 s and continuous acquisition 
to 95°C (ramp rate 0.02 °C/s), followed by cooling at 40°C for 10 s. Melting 
temperature for the DNA samples were assigned automatically by the Lightcycler ® 
480 Software. 
 
2.5.3 Statistical analyses 
For each DNA methylation assay, the difference in percentage of methylation in the 
pre- versus post-intervention sample was calculated for each individual. The assays 
were suitable for detecting changes of at least 10% or greater and therefore, 
individuals were placed in one of three categories: Up (> 10% increase in 
methylation); Down (< 10% decrease in methylation); No Change (< + or – 10%).  
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Tests for significance across categories were performed using a single-factor analysis 
of variance, ANOVA from Excel’s Analysis Toolpack add-in. 
 
3 Results 
3.1 Pilot genome wide screen identifies the RASA4 gene as a 
candidate human FS-DMR 
We performed a genome-wide DNA methylation analysis in a subset of the FASSTT 
samples (n = 6 individuals) in a bid to identify candidate FS-DMRs that would be 
subsequently screened in the entire cohort.  To minimize the amount of DNA 
methylation ‘noise’ due to non-folate related factors such as other environmental 
stimuli and individual genetic variation (McRae et al., 2014), we compared the DNA 
methylation profile of the same individual pre- and post- folic acid intervention (FA 
1-3) or placebo (Table 1) to identify putative FS-DMR. As expected, the folate status 
of those women who continued to take folic acid supplements from gestational week 
14 to 36 improved in line with what was previously reported for the rest of the cohort 
(McNulty et al., 2013), while those women taking placebo showed a drop in plasma 
folate status as is typically observed during pregnancy (Chanarin et al., 1968; Hall et 
al., 1976) and as previously reported for the rest of the cohort (McNulty et al., 2013) 
(Table 1).  
We applied Methylated DNA Immunoprecipitation (MeDIP) to all 12 samples 
(2 samples from each individual (pre- and post-intervention)). The samples underwent 
quantitative-PCR (qPCR) to ensure that the MeDIP and subsequent whole genome 
amplification ultimately yielded DNA that was enriched for the methylated fraction of 
the genome in a given sample in comparison to Input DNA (i.e., not 
immunoprecipitated). On average the MeDIP DNA was enriched 3.41 fold as 
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assessed by the H19 methylated DNA assay, and a decrease of 25 fold in the 
unmethylated DNA as assessed by the H3b unmethylated DNA assay.  Following 
these quality control measures, the 12 samples plus their Input DNA equivalents were 
sent to Nimblegen and hybridized to the Nimblegen Delux 2.1M promoter array.  This 
promoter array can assess the DNA methylation status of up to 28,266 CpG islands in 
close proximity to gene and miRNA promoters.  Nimblegen also performed a similar 
QC process prior to hybridization.   
We used a data analysis pipeline to identify candidate FS-DMR from the 
MeDIP analysis as described in Supplementary Information Figure 1 and in the 
Materials and Methods section. Our overall assessment of the DNA methylation 
profiles generated using the MeDIP method was that although methylation differences 
were detected in the pre- and post-intervention samples from the same individual in 
both the FA intervention and the placebo groups, there was very little consistency in 
the specific CpG sites that showed methylation differences.  We initially derived a list 
of potential FS-DMR sites in the promoter regions of 19 genes based on the peak 
score fold differences but the standard deviation and subsequent analysis of the 
individual peak scores reduced this number to 5. Of these 5, ultimately 4 were also 
rejected based on further analysis of the probes within the peak regions.  While the 
DEVA software assigns the same gene for a number of overlapping probes, we found 
that analysis of the raw data showed that the specific probes within the 4 candidate 
FS-DMR were different across our three FA intervention samples and therefore, these 
sites were not considered consistent. The one remaining candidate FS-DMR, Ras p21 
protein activator (RASA4; NM_001079877) promoter, was derived from the ‘On/Off’ 
list i.e., a gene promoter region that was considered methylated pre-intervention and 
then lost its methylation status post-intervention ('On/Off'). RASA4 showed a mean 
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fold methylation enrichment score of 7.27 in all three individuals (SD 1.49) in the FA 
pre-intervention samples and complete loss of methylation at the same promoter 
region after intervention (i.e., a score < 2.0).  The same promoter showed no change 
in methylation status in the placebo group pre- and post-intervention (average 0.96 
(SD 0.27)).   
 
3.2 Loss of DNA methylation at the RASA4 promoter correlates with 
an increase in gene expression in HEK293 cells exposed to 5-
azacytidine 
The relevance of DNA methylation status at the promoter of RASA4 was undertaken 
by assessing whether loss of global DNA methylation correlates with a gene specific 
loss of DNA methylation and with an increase in the abundance of RASA4 mRNA.  
We employed a cell culture model by exposure of HEK293 cells to 5-azacytidine 
resulting in passive global DNA de-methylation through inhibition of DNA 
methyltransferases (Schneider-Stock et al., 2005). Preliminary experiments identified 
5 M of 5-azacytidine as the highest dose of the drug that the cells can tolerate while 
still maintaining the capacity to double over a 7-day period. This effectively allows 
progressive passive DNA de-methylation at each cell doubling.  DNA and RNA were 
extracted at the end of the 7-day exposure and RASA4 specific DNA methylation and 
gene expression analyses were performed. Comparison of the level of DNA 
methylation (at sites between -158 bp and -81bp relative to the transcription start site 
of the RASA4 promoter) in the promoter of RASA4 showed a loss of methylation in 
the 5 M 5-azacytidine exposed cells compared to the control (0M) (Fig. 1a) using 
SMART-MSP. This RASA4 DNA de-methylation also resulted in an increase in gene 
expression level as assessed by RT-qPCR (Fig. 1b).  This suggests that specific DNA 
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methylation sites at the RASA4 promoter have a direct impact on the gene expression 
level of this gene and therefore, DNA methylation changes at this putative FS-DMR 
is likely to have functional biological relevance.   
  
  
3.3 DNA methylation analysis of candidate FS-DMR in the FASSTT 
cohort 
Our pilot genome wide screen in a subset of the FASSTT samples and our subsequent 
cell culture analyses identified RASA4 as a candidate FS-DMR.  We also identified a 
number of additional potential FS-DMR from the literature (Fryer et al., 2011; Parle-
McDermott et al., 2011; Vineis et al., 2011) and these included RASSF1A (Ras 
associated domain family member 1 alpha), EIF2C3 (Eukaryotic translation initiation 
factor 2C, 3) and ATPF1 (ATPase synthase H+ transporting, mitochondrial Fo 
complex, subunit B1). In addition, DHFR (Dihydrofolate reductase) and DHFR2 
(formerly known as DHFRL1: Dihydrofolate folate reductase like-1) formed part of 
the final candidate FS-DMR list given their central role in OCM and being the only 
enzymes capable of reducing folic acid (Bailey 1995; McEntee et al., 2011; Anderson 
et al., 2011).  We designed either a MS-HRM or a SMART-MSP assay to assess the 
DNA methylation status of specific CpG sites in the proximal promoters of each 
putative FS-DMR pre- versus post-intervention for each individual.   We chose a 
>10% change in the methylation status as the cut-off, given the limits of detection of 
our assays within this range and the lack of clarity in the field as to the relevance of 
DNA methylation of less than 10%.      
 RASA4, DHFR and DHFR2 were each examined by SMART-MSP and the 
pre- versus post-intervention methylation levels compared in each individual (Fig. 2). 
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The majority of individuals (88%) were unmethylated for RASA4 and showed no 
change in methylation status in the post- versus pre-intervention samples. There was 
no distinction between the FA intervention and the placebo group in this regard.  The 
small percentage of individuals that did show a methylation change showed either a 
variable increase or decrease in percentage methylation and again, there was no 
difference in the number of individuals from the FA intervention group compared to 
the placebo group.  DHFR2 was unmethylated in all samples tested, while DHFR 
showed a low level of methylation (10-20%) for the majority of samples tested (Fig. 
2) but similarly to RASA4, most individuals showed no change in methylation post-
intervention and those that did were variable and did not differentiate between the FA 
intervention and placebo groups.  Our analysis of RASSF1A, EIF2C3 and ATPF1 by 
MS-HRM showed that the regions examined were unmethylated in all of the samples 
examined by comparison to DNA methylation standards. In summary, our site-
specific DNA methylation analyses did not confirm our six candidates as definitive 
FS-DMR.  
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Discussion 
Our genome wide DNA methylation analysis on a subset of participants from the 
FASSTT trial (pre- versus post- intervention with folic acid) identified the promoter 
of RASA4 as a novel candidate FS-DMR but we were unable to confirm this in the 
rest of the cohort.  We did however, demonstrate that methylation loss at the RASA4 
promoter correlates with an increase in gene expression levels in HEK293 cells, 
indicating the functional relevance of DNA methylation at the control region of this 
gene (Fig. 1).  However, we do acknowledge that demonstration of DNA methylation 
control in a cell line may not be conserved in other tissues.   RASA4 is encoded on 
chromosome 7 and its protein product is a member of the GAP1 family of Ras 
GTPase-activating proteins (MIM: 607943) (Lockyer et al., 2001).  It plays a role in 
the regulation of Ras signalling at its various subcellular locations (Lockyer et al., 
2001; Bivona et al., 2003). Hypermethylation of RASA4 has been correlated with poor 
prognosis in juvenile myelomonocytic leukemia (Poetsch et al., 2014).  As our 
confirmatory DNA methylation analysis in all the FASSTT samples showed that the 
majority of samples were unmethylated and therefore, definitive conclusions on the 
relevance of the RASA4 as a possible FS-DMR could not be made. We suggest testing 
the response of RASA4 DNA methylation to folate status and/or folic acid intervention 
in other cohorts before a final conclusion can be made. Our site-specific DNA 
methylation analysis of RASSF1A, EIF2C3, ATPF1, DHFR and DHFR2 failed to 
provide evidence that the control regions of these genes are sensitive to folate status. 
 Our analyses of the same individuals pre- and post- intervention with folic 
acid for 22 weeks, did not identify FS-DMR sites in blood samples of pregnant 
women. We do acknowledge that a more site-specific, detailed methodology such as 
bisulphite Next Generation Sequencing (NGS) coupled with pyrosequencing and 
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larger study numbers may have yielded contrasting results to the negative findings 
that we achieved with MeDIP microarray and the melting PCR methods that we 
employed in this study. It is also possible that cord blood DNA may be more sensitive 
to methylation changes than the adult DNA samples that we examined in this 
manuscript due to the re-programming of DNA methylation patterns that occurs 
during development (Cedar and Bergman, 2012).  Moreover, a parallel study in the 
same cohort did examine a different set of candidate FS-DMR in the cord blood DNA 
samples (rather than the mother's DNA) and did identify differences in methylation 
patterns in the cords exposed to continued folic acid supplementation compared to 
placebo (Caffrey et al., 2018).   Another limitation is that both the placebo and FA 
intervention groups were taking a FA supplement up to the first trimester of 
pregnancy and therefore, the baseline folate status may have been too high to observe 
any meaningful folate-mediated changes.  Despite the limitations of our study, a 
search of the literature reveals a high level of inconsistency in the field in relation to 
the reported impact of folate status on methylation status in various gene targets 
(Parle-McDermott and Ozaki, 2011). It is good experimental laboratory practice to 
confirm a result with an alternative technique and many studies in this area have not 
done this (Fryer et al., 2011; Joubert et al., 2016).  Others reported significant 
increases or decreases in DNA methylation at specific sites, but with marginal 
percentage changes (Steegers-Theunissen et al., 2009; McCullough et al., 2016; 
Pauwels et al., 2017), which raises the question: What constitutes a biologically 
significant change in DNA methylation? Answering this will require a detailed 
analysis of which CpG sites have functional relevance for the control of the 
expression of a given gene and extensive knowledge on this has not been generated to 
date.  In other words, small changes in percentage DNA methylation may have 
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functional relevance but this has not been proven so far and needs to be elucidated on 
a gene-by-gene basis. Moreover, the position of the methylation site relative to the 
transcription start site is highly relevant for its potential functional significance in 
relation to gene control, and again requires a detailed investigation on a gene-by-gene 
basis.  
The biological plausibility of folate status having a direct impact on DNA 
methylation is strong, given that OCM is the provider of the methyl group through S-
adenosylmethionine (SAM). However, as we previously noted (Parle-McDermott and 
Ozaki, 2011), reported methylation changes in response to folate restriction show both 
increased and decreased levels indicating that the response is complex and it is not 
just a question of SAM supply.  There are numerous studies that indicate that markers 
of folate status do correlate with global measures of DNA methylation including 
HPLC measurements of methylated cytosines abundance (Friso et al., 2002) and 
LINE-1 element methylation (Badiga et al., 2016). This indicates that global DNA 
methylation per se is affected but it remains to be proven whether this translates into 
consistent site-specific DNA methylation changes that have actual biological 
relevance.   It is notable that a recent study observed that environmental influences on 
global DNA methylations patterns are minor relative to the effects of genetic 
differences between individuals (McRae et al., 2014).  
In conclusion, our analyses of human blood samples from a folic acid 
intervention trial did not find folate sensitive sites of large effect.  Further studies are 
required to assess whether FS-DMR are a feature of the human genome but closer 
attention needs to be paid to the molecular relevance of such changes and whether 
they have any impact on cellular function.  
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Figure 1. RASA4 promoter methylation and gene expression in response to 5-
azacytidine in HEK293 cells. 
(A) DNA methylation at -185 to -58 bp relative to the TSS in the RASA4 promoter 
was assessed by a SMART-MSP assay and confirms that HEK293 treatment with 5 
μM 5’azacytidine over 7 days resulted in passive de-methylation (p= 0.009) at this 
site. (B) 5-azacytidine treatment resulted in an increase in RASA4 mRNA level as 
assessed by RT-qPCR (p= 0.015).  
 
Figure 2.  DNA methylation analysis of candidate FS-DMR in the FASSTT study. 
SMART-MSP was used to examine DNA methylation at RASA4 (A), DHFR (B) and 
DHFR2 (C) and MS-HRM at RASSF1A (D), EIF2C3 (E) and ATPF1 (F). The number 
of CpG sites analysed is indicated by the lollipops including the region relative to the 
Transcription Start Site (TSS) for each gene.  The percentage methylation difference 
was calculated in the pre- versus post-intervention sample for each individual for both 
arms of the trial (folic acid (FA) or placebo) and then grouped by individuals that 
showed no change in methylation (-10% – +10%), increased methylation of more than 
10% (>10%) or decreased methylation of greater than 10% (<10%).  DHFR2, 
RASSF1A, EIF2C3 and ATPF1 showed no change in methylation in all individuals, 
while RASA4 and DHFR showed methylation changes in some individuals but there 
were no statistically significant differences between placebo and FA intervention 
groups (Single factor ANOVA analysis RASA4 (p= 0.9); DHFR (p= 0.404)).   
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Table 1. Samples selected from the FASSTT trial for the pilot genome-wide DNA 
methylation analysis 
Sample † Pre-Intervention Post-Intervention 
 pl. folate ‡ 
nmol/L 
RCF§ 
nmol/L 
Hcy ¶  
mol/L 
pl. folate 
nmol/L 
RCF 
nmol/L 
Hcy 
mol/L 
FA 1 23.4 497 4.9 42.0 1123 5.2 
FA 2 43.5 240 10.4 60.2 1540 6.9 
FA 3 43.8 848 5.5 72.8 1191 5.4 
Placebo 1 18.2 378 14.2 5.6 425 14.0 
Placebo 2 50.0 942 5.7 15.2 623 6.7 
Placebo 3 42.9 750 4.5 13.4 802 4.9 
† Samples with ‘FA’ in the identifier are those individuals in the folic acid arm of the intervention trial; 
samples with ‘Placebo’ in the identifier are those individuals in the placebo arm of the intervention 
trial.   
‡ pl. folate = plasma folate 
§ RCF = red cell folate 
 ¶ Hcy = plasma homocysteine  
 
 
 
 
